Pyridoclax
Code | Size | Price |
---|
TAR-T16694-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T16694-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Pyridoclax is an inhibitor of potential Mcl-1.
CAS:
1651890-44-6
Formula:
C29H22N4
Molecular Weight:
426.523
Pathway:
Apoptosis
Purity:
0.98
SMILES:
Cc1cc(cnc1-c1cccnc1)-c1ncc(cc1C=Cc1ccccc1)-c1cccnc1
Target:
BCL
References
1. Gloaguen C, et al. First evidence that oligopyridines, ?-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies. J Med Chem. 2015 Feb 26;58(4):1644-68.
2. Groo AC, et al. Comparison of 2 strategies to enhance Pyridoclax solubility: Nanoemulsion delivery system versus salt synthesis. Eur J Pharm Sci. 2017 Jan 15;97:218-226.